RxDoctor Payments DataLook up a doctor →

Wayne Warren, MD

Internal Medicine · New Haven, CTNPI 1447220496

Payments from drug & device makers

$126,785in general payments, 2019–2025

Across 894 payments — averaging $141.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$92K
  • Amarin Pharma, Inc.$17K
  • GSK$7K
  • Novo Nordisk$2K
  • Sanofi-aventis U.S. LLC$1K
  • Boehringer Ingelheim$1K
  • plus $6K from 19 others

What the payments were for

  • Consulting fees$7,7376%
  • Speaking & faculty fees$89,22770%
  • Travel & lodging$9,2417%
  • Food & beverage$20,16616%
  • Education$4140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,785 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$62,450
Medicare patients
92
Services billed
862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$107,828
EliquisApixaban59$80,957
JardianceEmpagliflozin41$58,030
FarxigaDapagliflozin Propanediol47$56,929
Repatha SureclickEvolocumab40$51,910
VascepaIcosapent Ethyl48$41,954
MounjaroTirzepatide22$33,961
MyrbetriqMirabegron18$24,271
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$19,727
JanuviaSitagliptin Phosphate14$16,664
Breo ElliptaFluticasone/Vilanterol13$6,150
Rosuvastatin Calcium452$5,721
Icosapent Ethyl13$3,696
Atorvastatin Calcium382$3,580
Testosterone17$3,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,099$107,82857 claims
PfizerEliquis$125$80,95759 claims
Boehringer IngelheimJardiance$1,272$58,03041 claims
AstraZenecaFarxiga$890$56,92947 claims
Lilly USA, LLCMounjaro$584$33,96122 claims
Astellas Pharma US IncMyrbetriq$1,096$24,27118 claims
MerckJanuvia$333$16,66414 claims
GSKBreo Ellipta$7,280$6,15013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →